ICAT and its variations have become the gold standard for comparing global protein expression in many proteomics labs. But they may soon be rivaled by another strategy, recently published by Steven Gygi’s group at Harvard. Termed “Aqua” for absolute quantification, it promises to allow users to measure a small number of proteins — or their modification states — in large numbers of biological samples. Aqua assays are slated to be commercialized soon by Cell Signaling Technology, a company based in Beverly, Mass.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.